Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • ERS author centre
    • COVID-19 submission information
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • ERS author centre
    • COVID-19 submission information
  • Alerts
  • Subscriptions

Symptomatic hypercalcaemia in paediatric tuberculosis

H.A. Payne, E. Menson, M. Sharland, P.A. Bryant
European Respiratory Review 2011 20: 053-056; DOI: 10.1183/09059180.00006910
H.A. Payne
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: helenpayne@doctors.org.uk
E. Menson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Sharland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P.A. Bryant
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

To the Editors:

A 13-yr-old Congolese female presented in early spring with a 6-month history of productive cough, progressive exertional dyspnoea and weight loss of 4.5 kg. 2 weeks prior to presentation she had developed high fevers and increasing lethargy. She had immigrated to the UK at the age of 2 yrs. She had not been overseas since and there was no history of contact with anyone with tuberculosis (TB). She had no past medical history and was fully immunised except for bacilli Calmette–Guérin.

On examination she was cachectic and lethargic. There were no signs of clubbing, rickets or oedema. Her weight was 34 kg (less than third centile), height 148 cm (10th centile) and body mass index 15 kg·m−2 (less than first centile). She was tachycardic and tachypnoeic with oxygen saturations of 90% in air. There was dullness to percussion and widespread coarse crackles on auscultation throughout the left lung field and at the right apex. The chest radiograph showed extensive left lung and right upper lobe consolidation (fig. 1). Her C-reactive protein was 160 mg·L−1 and erythrocyte sedimentation rate was 90 mm·h−1. Her corrected calcium and phosphate were low, 1.96 mmol·L−1 (normal range 2.18–2.47 mmol·L−1) and 0.80 mmol·L−1 (0.75–1.50 mmol·L−1), respectively, with albumin and alkaline phosphatase levels of 23 g·L−1 (35–40 g·L−1) and 118 mmol·L−1 (30–200 mmol·L−1), respectively. Her Mantoux test was strongly positive (20 mm induration) and acid-fast bacilli were present in her sputum, which subsequently cultured Mycobacterium tuberculosis. In addition to consolidation, her chest computed tomography scan showed cavities within the distal bronchi, widespread tree-in-bud appearances throughout the left lower lobe and extensive mediastinal, paratracheal and subcarinal adenopathy. Standard quadruple anti-tuberculous therapy (isoniazid, rifampicin, ethambutol and pyrazinamide) was started. In view of her malnutrition, nasogastric (NG) tube feeds were also commenced. Her serum 25-hydroxy-vitamin D3 level, taken prior to starting anti-tuberculous therapy, was low at 20 nmol·L−1 (normal range 75–200 nmol·L−1), therefore supplementation with ergocalciferol (vitamin D2) 10,000 IU·day−1 was initiated. On discharge from hospital 20 days later her serum calcium was within the normal range.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Calcium and vitamin D metabolism. Continuous arrows represent movement of calcium and vitamin D and its metabolites. Dashed arrows represent the effects of vitamin D and hormones on calcium. Dotted arrows represent potential mechanisms of hypercalcaemia in tuberculosis. The chest radiography of our patient is included and shows extensive pulmonary consolidation and lack of subcutaneous tissue. PTH: parathyroid hormone.

1 week later she represented with nausea and vomiting, abdominal pain and aching muscles. Her respiratory symptoms had improved but she was continuing to lose weight and appeared very low in mood. Her serum calcium level was very high at 3.74 mmol·L−1, with phosphate and albumin levels of 1.60 mmol·L−1 and 33 g·L−1, respectively. Urinary calcium was high at 7.82 mmol·L−1 (1.87–3.39 mmol·L−1), although her renal function tests were normal. The 1,25-dihydroxy-vitamin D3 level was also high at 311 pmol·L−1 (40–150 pmol·L−1). Her parathyroid hormone was low at <0.7 pmol·L−1 (1.1–6.9 pmol·L−1) and 25-hydroxy-vitamin D3 was normal at 144 nmol·L−1 (75–200 nmol·L−1). The ergocalciferol supplements, which she had been taking for 28 days, were stopped and NG feeding was restarted with reduced calcium. Her symptoms of hypercalcaemia improved rapidly but serum calcium remained high so she was started on intravenous fluids. Her serum calcium gradually decreased over several days. 3 months later she remains on anti-tuberculous treatment and the hypercalcaemia has not recurred.

The two sources of vitamin D in humans are metabolism in the skin in response to sunlight, and ingestion and absorption via the intestine (fig. 1). Vitamin D3 (cholecalciferol; the most abundant form) is partially hydroxylated in the liver to form 25-hydroxy-vitamin D3 (25(OH)D3; calcidiol) which is then further hydroxylated in the kidney to form 1,25-dihydroxy-vitamin D3 (1,25(OH)2D3; calcitriol). The latter is the active form of vitamin D3 which causes increased gastrointestinal absorption of calcium, osteoclastic resorption from bone and renal tubular resorption, raising serum calcium levels. In addition, vitamin D inhibits parathyroid hormone which regulates serum calcium levels.

Hypercalcaemia has been described in adult patients with most granulomatous disorders, including TB, although the majority are asymptomatic. Rates of hypercalcaemia in TB in adults vary widely from 6 to 48% [1, 2]. Symptomatic hypercalcaemia in TB is less common, with rates of ∼3% in adults [3], although there are no data in children. Allowing for variation in methodology, differences between populations are probably due to sun exposure and diet, particularly the latter.

Attempts to predict which patients will develop hypercalcaemia have been unsuccessful as there is no clear relationship between serum calcium level and type or stage of disease: some patients are hypercalcaemic at diagnosis, while others develop hypercalcaemia while on treatment. In addition, there is discrepancy between studies correlating serum calcium levels and radiological extent of disease, with some finding an association and others finding no relationship.

There are only a few cases in the literature over the last 25 yrs which have reported children with hypercalcaemia associated with TB, often with severe disease (table 1) [4–10]. Our case describes a teenage female with extensive pulmonary TB associated with symptomatic hypercalcaemia that persisted despite cessation of vitamin D supplementation. It is the first report of symptomatic hypercalcaemia in a child on both anti-tuberculous therapy and vitamin D supplementation.

View this table:
  • View inline
  • View popup
Table 1. Clinical and biochemical data of all cases of hypercalcaemia in tuberculosis (TB) reported in children in the past 25 yrs

The mechanism underlying hypercalcaemia in TB is thought to be over-production of 1,25(OH)2D3 in extra-renal macrophages in granulomas, for example in the alveoli. It has been suggested that the production of 1,25(OH)2D3 has a protective effect against oxidative injuries from the nitric oxide burst from granulomatous macrophages [11]. This was initially studied in other granulomatous diseases, such as sarcoidosis. In TB, 1,25(OH)2D3 has been shown to be produced by alveolar macrophages from a patient with pulmonary TB [12], and high serum levels have been found in anephric patients, further supporting an extra-renal source [13]. Because production is extra-renal, the normal feedback control of 1,25(OH)2D3 production by parathyroid hormone is ineffective.

However, TB-associated hypercalcaemia has also been reported in patients with normal [4] and low [14] levels of serum 1,25(OH)2D3. Other causes may include an overdose of vitamin D or calcium supplements. An alternative possibility is abnormal activation of parathyroid hormone-related protein, which is the usual aetiological agent of hypercalcaemia of malignancy and is raised in some patients with sarcoidosis [15].

Recent studies have focussed on the association between low vitamin D levels and active TB [16]. However, despite investigation of vitamin D levels and supplementation becoming increasingly common in clinical practice, the mechanism is not fully understood. This case raises the possibility that extra-renal production of 1,25(OH)2D3 in TB may inappropriately lower serum 25(OH)D3 resulting in, or at least contributing to, this finding.

It is likely that the hypercalcaemia in our patient was multifactorial. Normal 25(OH)D3 and high 1,25(OH)2D3 indicate that the hypercalcaemia was secondary to granulomatous disease rather than vitamin D toxicity. However, the fact that our patient was not hypercalcaemic at presentation suggests that it may not have been due to disease alone. The vitamin D supplementation would have increased calcium absorption from the intestine at the same time as she was receiving highly nutritious NG feeds. It is likely that this, in combination with extra-renal 1,25(OH)2D3 production, explains her hypercalcaemic state.

The management of hypercalcaemia in TB involves treatment of the underlying cause, together with measures to reduce the serum calcium. Restriction of calcium and vitamin D supplements is sometimes all that is required, although intravenous fluids may be used for more rapid normalisation of serum levels. A variety of other treatments have been used: ketoconazole, hydroxychloroquine, bisphosphanates and corticosteroids [6, 8, 17]. The mechanisms for these therapeutic measures are not fully understood, although corticosteroids are believed to reduce the concentration of 1,25(OH)2D3 by inhibiting hydroxylation to this metabolite [16]. Unless absolutely necessary, polypharmacy should be avoided as patients already have a significant medication burden and additional medications may affect compliance. In our case supplement restriction and intravenous hydration was sufficient.

Our case illustrates the infrequently recognised and poorly understood phenomenon of hypercalcaemia in TB. Children with TB are increasingly being tested and treated for vitamin D deficiency. However, there are no clear guidelines for dosage and duration of supplementation, and further studies are needed to address this. It is therefore important to monitor serum calcium and vitamin D levels especially after starting concurrent supplementation and nutrition, and to have a high index of suspicion for hypercalcaemia when presented with gastrointestinal or musculoskeletal symptoms.

Footnotes

  • Provenance

    Submitted article, peer reviewed.

  • Statement of Interest

    None declared.

  • ©ERS 2011

REFERENCES

  1. ↵
    1. Chan TY,
    2. Chan CH,
    3. Shek CC
    . The prevalence of hypercalcaemia in pulmonary and miliary tuberculosis: a longitudinal study. Singapore Med J 1994; 35: 613–615.
    OpenUrlPubMed
  2. ↵
    1. Kitrou MP,
    2. Phytou-Pallikari A,
    3. Tzannes SE,
    4. et al
    . Serum calcium during chemotherapy for active pulmonary tuberculosis. Eur J Respir Dis 1983; 64: 347–354.
    OpenUrlPubMed
  3. ↵
    1. Roussos A,
    2. Lagogianni I,
    3. Gonis A,
    4. et al
    . Hypercalcaemia in Greek patients with tuberculosis before the initiation of anti-tuberculosis treatment. Respir Med 2001; 95: 187–190.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Ayonrinde OT,
    2. Zimmerman MJ
    . Ascites, hypercalcaemia, diffuse peritoneal thickening and elevated OM-MA in a fifteen-year-old girl (a case of peritoneal tuberculosis). Intern Med J 2004; 34: 216–217.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Gaskin KJ,
    2. Vines RH
    . Hypercalcaemia: an unusual complication of tuberculosis. A case report. Aust Paediatr J 1978; 14: 44–47.
    OpenUrlPubMed
  6. ↵
    1. Gerritsen J,
    2. Knol K
    . Hypercalcaemia in a child with miliary tuberculosis. Eur J Pediatr 1989; 148: 650–651.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Okascharoen C,
    2. Nuntnarumit P,
    3. Sirinavin S
    . Neonatal tuberculosis associated with shock, disseminated intravascular coagulation, hemophagocytic syndrome, and hypercalcemia: a case report. J Perinatol 2003; 23: 79–81.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Saggese G,
    2. Bertelloni S,
    3. Baroncelli GI,
    4. et al
    . Ketoconazole decreases the serum ionized calcium and 1,25-dihydroxyvitamin D levels in tuberculosis-associated hypercalcemia. Am J Dis Child 1993; 147: 270–273.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Saggese G,
    2. Bertelloni S,
    3. Baroncelli GI,
    4. et al
    . [Abnormal synthesis of 1,25-dihydroxyvitamin D and hypercalcemia in children with tuberculosis]. Pediatr Med Chir 1989; 11: 529–532.
    OpenUrlPubMed
  10. ↵
    1. Tresoldi AT,
    2. Pereira RM,
    3. Castro LC,
    4. et al
    . [Hypercalcemia and multiple osteolytic lesions in a child with disseminated paracoccidioidomycosis and pulmonary tuberculosis]. J Pediatr (Rio J) 2005; 81: 349–352.
    OpenUrlPubMed
  11. ↵
    1. Chang JM,
    2. Kuo MC,
    3. Kuo HT,
    4. et al
    . 1-alpha,25-Dihydroxyvitamin D3 regulates inducible nitric oxide synthase messenger RNA expression and nitric oxide release in macrophage-like RAW 264.7 cells. J Lab Clin Med 2004; 143: 14–22.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Cadranel J,
    2. Hance AJ,
    3. Millerson B,
    4. et al
    . Vitamin D metabolism in tuberculosis: production of 1,25(OH)2D3 by cells recovered from bronchoalveolar lavage and the role of this metabolite in calcium homeostasis. Am Rev Respir Dis 1988; 138: 984–989.
    OpenUrlPubMed
  13. ↵
    1. Gkonos PJ,
    2. London R,
    3. Hendler ED
    . Hypercalcaemia and elevated 1.25-dihydroxyvitamin D levels in a patient with end-stage renal disease and active tuberculosis. N Engl J Med 1984; 311: 1683–1685.
    OpenUrlPubMed
  14. ↵
    1. Meuthen I,
    2. Kirsch L,
    3. Saborowski F
    . [Hypercalcemia in florid pulmonary and cervical lymph node tuberculosis]. Dtsch Med Wochenschr 1991; 116: 899–902.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Zeimer HJ,
    2. Greenaway TM,
    3. Slavin J,
    4. et al
    . Parathyroid-hormone-related protein in sarcoidosis. Am J Pathol 1998; 152: 17–21.
    OpenUrlPubMed
  16. ↵
    1. Nnoaham KE,
    2. Clarke A
    . Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. Int J Epidemiol 2008; 37: 113–119.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Isaacs RD,
    2. Nicholson GI,
    3. Holdaway IM
    . Miliary tuberculosis with hypercalcaemia and raised vitamin D concentrations. Thorax 1987; 42: 555–556.
    OpenUrlFREE Full Text
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 20 Issue 119 Table of Contents
  • Table of Contents
  • Table of Contents (PDF)
  • Cover (PDF)
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Symptomatic hypercalcaemia in paediatric tuberculosis
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Symptomatic hypercalcaemia in paediatric tuberculosis
H.A. Payne, E. Menson, M. Sharland, P.A. Bryant
European Respiratory Review Mar 2011, 20 (119) 053-056; DOI: 10.1183/09059180.00006910

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Symptomatic hypercalcaemia in paediatric tuberculosis
H.A. Payne, E. Menson, M. Sharland, P.A. Bryant
European Respiratory Review Mar 2011, 20 (119) 053-056; DOI: 10.1183/09059180.00006910
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Barium oesophagography in patients with suspected trachea-oesophageal fistula
  • 2-year survival among elderly hospitalised for acute respiratory infection versus hip fracture: a useful comparison to raise awareness
  • Air dispersion and oronasal masks with CPAP during COVID-19
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERR

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising
  • Sponsorship

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 0905-9180
Online ISSN: 1600-0617

Copyright © 2021 by the European Respiratory Society